Please login or register to print this page.

Clinical Articles, Lead Article

Angina drug benefits for liver cancer

Anti-anginal agent perhexiline is one of 101 compounds predicted to prevent cancer growth in patients suffering from hepatocellular carcinoma (HCC), according to a study published recently in Molecular Systems Biology.1

Researchers generated personalised proteomics data for HCC patients using the antibodies produced in the Human Protein Atlas project. The researchers then generated individual computer models for six HCC patients based on their personal set of proteins and a generic map of human metabolism.

The six personal models were then used to find potential new anti-cancer drugs. By simulating the effect of all possible antimetabolites, the computer generated potential anti-cancer drugs which could be effective in inhibiting tumour growth.

Furthermore, the researchers simulated the effect of these antimetabolites on 83 major healthy cell types in human body to predict their toxic effects. This led to the identification of 101 antimetabolites which were predicted to prevent cancer growth in all six studied HCC patients, whereas 46 antimetabolites inhibited tumour growth only in one or a few of the patients. All 147 were predicted to not be overly toxic to healthy cells.

“With this approach we can find and evaluate new potential drugs, some that could be used for general treatment of HCC, and others that are highly specific for each HCC patient. We can also predict false positive drug targets that would not be effective in all patients. This would lead to more targeted and efficient cancer treatment,” said co-author Dr Adil Mardinoglu (Chalmers University of Technology, Sweden).

One of the antimetabolites, perhexiline, was tested in vitro on a liver cancer cell line. As a continuation of this study, perhexiline will be tested on other cancer cell lines, since the researchers believe it may inhibit growth in other types of cancer as well.

Illustration of the Genome-scale metabolic models

Illustration of the Genome-scale metabolic models

References

1. Agren R, Mardinoglu A, Asplund A, Kampf C, Uhlen M, Nielsen J. Mol Syst Biol 2014;10:721. http://dx.doi.org/10.1002/msb.145122

Published on: March 28, 2014

Members Area

Log in or Register now.

 For healthcare professionals only
Anticoagulation sky

SEARCH THE SITE

RSS FEED

Subscribe to our RSS feed
home

GET EXCLUSIVE UPDATES

Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.

RECENT COMMENTS

    None Found

ENDORSED BY

  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association
 

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.